Brain & Nervous System Multiple Sclerosis Treatment Treating MS With Intravenous Immunoglobulin (IVIG) By Julie Stachowiak, PhD Updated on November 26, 2023 Medically reviewed by Brigid Dwyer, MD Print Table of Contents View All Table of Contents Uses Effectiveness Side Effects Interactions/Warnings Cost Intravenous immunoglobulin (IVIG) is a type of therapy in which a mixture of antibodies (immunoglobulins)—defensive proteins produced by your body in response to a disease—is injected into a vein over the course of several days with the aim of improving your immune function. IVIG is believed to help treat multiple sclerosis (MS) and other neurological diseases by stimulating certain parts of the immune system and suppressing others. However, no one knows for certain how it works. As such, IVIG is prescribed off-label—without specific approval by the U.S. Food and Drug Administration (FDA)—for diseases in which your immune system is severely compromised. These conditions may include neonatal sepsis, pediatric HIV, and certain cases of advanced HIV. IVIG is also used as a second-line treatment for relapsing-remitting multiple sclerosis (RRMS). moodboard/Cultura/Getty Images Uses While there's no clear consensus as to when IVIG treatment for MS is most appropriate, it has shown promise in a number of specific areas, including: Preventing MS relapse in postpartum pregnancy Treating people who have failed first-line treatment for RRMS and are unable to tolerate traditional disease-modifying drugs Understanding Clinically Isolated Syndrome Effectiveness At this time, no one really knows how effective IVIG is in treating or slowing the progression of MS. Most of the evidence has been based on its effects on other neurological diseases, such as Guillain-Barré syndrome and myasthenia gravis. Studies focused purely on IVIG and MS have been mixed at best. One Austrian study did show a small but statistically significant improvement in disability as measured by the expanded disability status scale (EDSS). Others have shown a slight improvement in the size or number of brain lesions on a magnetic resonance imaging (MRI) scan. Other studies, meanwhile, have shown no difference in the effectiveness of IVIG compared to placebos in treating RRMS. Perhaps the one area of promise is the use of IVIG right after childbirth, which has been shown to significantly reduce the rate of relapses in new mothers. Side Effects The most common side effect of IVIG is a headache, which can usually be treated with an over-the-counter painkiller like Tylenol (acetaminophen) or Advil/Motrin (ibuprofen). Other possible side effects include: FeverJoint painChest painVomitingNauseaFatigueDizzinessChillsRash (less common)Fluid overload Rare Side Effects Some rare but serious side effects have also been noted, including: Aseptic meningitis Heart attack Stroke Deep vein thrombosis Kidney dysfunction Kidney failure Interactions and Contraindications IVIG should not be used in people with kidney problems or IgA deficiency, a genetic disorder characterized by the lack of an antibody that protects against infections in the mouth, airways, and digestive tract. IVIG should be used with caution in people with the following conditions: Heart problemsDiabetesSensitivity to immunoglobulinsSensitivity to maltose or sucrose (ingredients used in some IVIG formulations) The only clearly defined interaction with IVIG involves live vaccines. Immunoglobulins can render a vaccine ineffective and void any protection the vaccine may afford. Cost IVIG has become extremely expensive at an estimated $100 per gram. For a person weighing 154 pounds (70 kilograms), the recommended monthly dosage would end up costing around $7,000 per infusion, not including facility administration and nursing costs. Some insurance companies may cover the cost, but it's often difficult to motivate for treatment and usually requires an appeals process to finally gain approval. If approved, insurance co-pays can be extremely high. However, some IVIG manufacturers do offer patient assistance programs (PAPs) to either defray or entirely cover the cost of treatment. A Word From Verywell If your healthcare provider recommends IVIG, you may need to advocate for yourself to get approval from your insurance. It's also important to understand the benefits and limitations of the proposed treatment—essentially what the research says and doesn't say. If you're not absolutely clear about this, don't hesitate to seek a second opinion from a qualified specialist. You can use our Doctor Discussion Guide below to help you start that conversation. Multiple Sclerosis Doctor Discussion Guide Get our printable guide for your next doctor's appointment to help you ask the right questions. Download PDF Sign up for our Health Tip of the Day newsletter, and receive daily tips that will help you live your healthiest life. Email Address Sign Up You're in! Thank you, {{form.email}}, for signing up. There was an error. Please try again. 6 Sources Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy. Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol. 2017;29(11):491-498. doi:10.1093/intimm/dxx039 Gilardin L, Bayry J, Kaveri SV. Intravenous immunoglobulin as clinical immune-modulating therapy. CMAJ. 2015;187(4):257–264. doi:10.1503/cmaj.130375 Bayry J, Hartung HP, Kaveri SV. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties. Trends Pharmacol Sci. 2015;36(7):419-421. doi:10.1016/j.tips.2015.04.012 Lünemann JD, Quast I, Dalakas MC. Efficacy of intravenous immunoglobulin in neurological diseases. Neurotherapeutics. 2016;13(1):34–46. doi:10.1007/s13311-015-0391-5 Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299. doi:10.3389/fimmu.2018.01299 Children's Hospital of Philadelphia. Intravenous immunoglobulin (IVIG). Additional Reading Winkelmann A, Rommer PS, Hecker M, Zettl UK. Intravenous Immunoglobulin Treatment in Multiple Sclerosis: A Prospective, Rater-Blinded Analysis of Relapse Rates During Pregnancy and the Postnatal Period. CNS Neuroscience & Therapeutics. 2019;25(1):78–85. doi:10.1111/cns.12985. By Julie Stachowiak, PhD Julie Stachowiak, PhD, is the author of the Multiple Sclerosis Manifesto, the winner of the 2009 ForeWord Book of the Year Award, Health Category. See Our Editorial Process Meet Our Medical Expert Board Share Feedback Was this page helpful? Thanks for your feedback! What is your feedback? Other Helpful Report an Error Submit